Navigation Links
Blood test may identify lung cancer patients likely to respond to erlotinib
Date:4/30/2010

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

Erlotinib is one of a class of drugs that specifically inhibits an important cell-surface molecule known as the epidermal growth factor receptor (EGFR), which is highly expressed in some forms of cancer, including lung cancer. By blocking this receptor, drugs such as erlotinib aim to slow tumor growth and proliferation.

Prof David Carbone from Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Canadian colleagues analyzed blood samples from the NCIC Clinical Trials Group (NCIC CTG) BR.21 study that had shown that erlotinib improved survival compared to placebo in patients with advanced non-small-cell lung cancer who had already tried one or two other drugs.

In the new study, the researchers analyzed blood samples that had been taken from some patients before they started treatment in the BR.21 study. They performed this analysis on patients who received the drug and on patients who received the placebo, looking for specific proteomic profiles already known to predict outcomes in patients treated with EGFR-blockers.

"The bottom line is that the proteomic test --comparing 'good' and 'poor' profiles-- was strongly prognostic in both erlotinib and placebo arms," said Prof Carbone. "Proteomics 'good' patients also had a significantly higher response rate than proteomics 'poor' patients (9.8% vs. 0.9%, p=0.002).

Prof Carbone notes that there are other methods available to analyze the EGFR pathway of lung cancers, including sequencing of the EGFR gene, or a technique known as fluorescence in-situ hybridization (FISH) to assess EGFR gene copy number, in which tumor tissue samples are directly studied under a microscope.

"FISH overall was a better predictor of benefit, but can only be done with adequate biopsy tissue, which was available in this study only in 22% of patients. With the serum test, 99% of patients had a successful determination of proteomic status."

"Thus, I think this test may be of potential value in identifying a subgroup of patients with a good prognosis and who are likely to have response to erlotinib; it may be of particular value for those in whom tumor tissue is inadequate or unavailable," Prof Carbone said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Blood stem-cell transplant regimen reverses sickle cell disease in adults
2. Blood Thinner Combos Risky for Heart Attack Patients
3. China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
4. A better sign of blood vessel narrowing and early coronary artery disease
5. American Red Cross and Other U.S. Blood Centers Send Blood to Haiti
6. Analysis Examines Ultrasound Use for Blood Clots
7. Minnesota Vikings Team With Memorial Blood Centers Again for Annual Blood Drive
8. Newly discovered mechanism by which blood clots form
9. Long Before Symptoms, Blood May Reveal Rheumatoid Arthritis
10. Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says
11. Hematologists Can Now Earn CME Credits Through the Journal Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... Caduceus International Publishing (CIP), a ... a new online course entitled Personal & Community Health for the ... for achieving optimal well-being and teaches students how to apply them in their ...
(Date:6/20/2017)... ... June 20, 2017 , ... Kenneth Mayer, MD, has been appointed ... , Dr. Mayer, who joined the JIAS Editorial Board in 2016, has co-authored more ... Director of Fenway Health and Co-Chair of The Fenway Institute, a member ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... AMC ... continued expansion and success in the clinical trials market. Similar to its approach in ... record in the clinical trials marketplace by proving the value of eVisits to support ...
(Date:6/20/2017)... Ohio (PRWEB) , ... June 20, 2017 , ... ... gum disease in Cincinnati, OH for leading-edge care, whether or not ... in laser dentistry. Using the BIOLASE WaterLase® iPlus™ laser, she targets bacteria and ...
(Date:6/20/2017)... PA (PRWEB) , ... June 20, 2017 , ... ... at Allegheny Health Network’s (AHN) Jefferson Hospital is providing physicians with advanced capabilities ... scanner provides higher-resolution images than traditional MRIs, enabling doctors to get a more ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
(Date:6/1/2017)... Nutriceutical Holdings (NH), parent company of Physician ... KD Pharma Group have decided to join forces through ... Group. KD Pharma Group will become the largest shareholder ... entire company. "We believe we have found ... growing the NH companies by providing us with supply ...
(Date:5/26/2017)... International plc (NASDAQ: ENDP ) announced today that ... Company in a fireside chat at Goldman Sachs, 38 th ... at 10:40 a.m. PT / 1:40 p.m. ET. The conference ... Palos Verdes, CA. A live webcast ... the Company,s website at http://www.endo.com/investors/overview . Participants should allow ...
Breaking Medicine Technology: